Moderna gains as RSV shot prevents most cases in older people
Though some months behind other competitors, Moderna’s shot is the only mRNA-based contender for the RSV market, for which it could win approval this year.
By Angelica Peebles and Robert Langreth, bloomberg
Moderna Inc.’s vaccine against RSV was highly effective in preventing the lung disease in older people, paving the way for the company to seek its first approval outside Covid-19.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
First protective RSV option one step closer to market
For subscribers
Bavarian Nordic meets recruitment target for RSV study
For subscribers
